EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Systemic delivery of phagocytosis-shielded retroviral vectors enables in vivo HSC gene therapy for sickle cell disease

Denise Klatt, Adele Mucci, Boya Liu, Marie Peschers, Giulia Schiroli, Axel Schambach, John Manis, Myriam Armant, David T Scadden, Els Verhoeyen, Danilo Pellin, David A Williams und 1 weitere

Cell Stem Cell · 2026-10 · 33 (10) · 1643-1657.e5

DOI: 10.1016/j.stem.2026.09.001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Stem Cell, 2026-10. Verfasst von Denise Klatt und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, B…. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Genetic Therapy, Genetic Vectors, Hematopoietic Stem Cells. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bill & Melinda Gates Foundation, NHLBI NIH HHS, German Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellGenetic TherapyGenetic VectorsHematopoietic Stem CellsPhagocytosisRetroviridaeGene Transfer TechniquesAnimalsHumansMiceGene Therapy Agents

Stichwörter der Autor:innen

BaEVHSCSCDalpha-retroviral vectorbaboon endogenous retrovirus glycoproteinhematopoietic stem cellin vivo gene therapylentiviral vectorsickle cell disease

Autor:innen und Institutionen

  • Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Department of Pediatrics, Harvard Medical School…
  • Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA; Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA.
  • Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA.
  • Krantz Family Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA.
  • Institute of Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany.
  • Department of Laboratory Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.

Förderung

  • Bill & Melinda Gates Foundation
  • NHLBI NIH HHS
  • German Research Foundation
  • National Heart Lung and Blood Institute
  • Gates Foundation

Zitieren

APA

Klatt, D., Mucci, A., Liu, B., Peschers, M., Schiroli, G., Schambach, A., Manis, J., Armant, M., Scadden, D. T., Verhoeyen, E., Pellin, D., Williams, D. A., & Brendel, C. (2026). Systemic delivery of phagocytosis-shielded retroviral vectors enables in vivo HSC gene therapy for sickle cell disease. Cell Stem Cell, 33(10), 1643-1657.e5. https://doi.org/10.1016/j.stem.2026.09.001

Vancouver

Klatt D, Mucci A, Liu B, Peschers M, Schiroli G, Schambach A, et al. Systemic delivery of phagocytosis-shielded retroviral vectors enables in vivo HSC gene therapy for sickle cell disease. Cell Stem Cell. 2026;33(10):1643-1657.e5. doi:10.1016/j.stem.2026.09.001

BibTeX
@article{Klatt2026,
  author = {Klatt, Denise and Mucci, Adele and Liu, Boya and Peschers, Marie and Schiroli, Giulia and Schambach, Axel and Manis, John and Armant, Myriam and Scadden, David T and Verhoeyen, Els and Pellin, Danilo and Williams, David A and Brendel, Christian},
  title = {Systemic delivery of phagocytosis-shielded retroviral vectors enables in vivo HSC gene therapy for sickle cell disease},
  journal = {Cell Stem Cell},
  year = {2026},
  volume = {33},
  number = {10},
  pages = {1643--1657.e5},
  doi = {10.1016/j.stem.2026.09.001}
}
Kostenlos starten →